Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways.
A highly reproducible quantitative PCR (Q-PCR) assay was used to study the stability of human papillomavirus (HPV) in undifferentiated keratinocytes that maintain viral episomes. The term "stability" refers to the ability of episomes to persist with little copy number variation in cells. In investigating the mechanism of action of PA25, a previously published compound that destabilizes HPV episomes, aphidicolin was also found to markedly decrease episome levels, but via a different pathway from that of PA25. Since aphidicolin is known to activate DNA damage response (DDR) pathways, effects of inhibitors and small interfering RNAs (siRNAs) acting within DDR pathways were investigated. Inhibitors of Chk1 and siRNA directed against ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia Rad3-related (ATR) pathways significantly reduced viral episomes, suggesting that these pathways play a role in maintaining HPV episome stability. Inhibitors of Chk2 and DNA-PK had no effect on episome levels. Pharmacological inhibition of ATM proteins had no effect on episome levels, but ATM knockdown by siRNA significantly reduced episome levels, suggesting that ATM proteins are playing an important role in HPV episome stability that does not require kinase activity. These results outline two pathways that trigger episome loss from cells and suggest the existence of a little-understood mechanism that mediates viral DNA elimination. Together, our results also indicate that HPV episomes have a stability profile that is remarkably similar to that of fragile sites; these similarities are outlined and discussed. This close correspondence may influence the preference of HPV for integration into fragile sites.
NanoVir, Kalamazoo, Michigan, USA.
Terri G
TG
Edwards
Michael J
MJ
Helmus
Kevin
K
Koeller
James K
JK
Bashkin
Chris
C
Fisher
D052685:Alphapapillomavirus / Q000235:genetics*; D016590:Aphidicolin / Q000494:pharmacology*; D015139:Blotting, Southern; D015153:Blotting, Western; D064447:Checkpoint Kinase 2; D056915:DNA Copy Number Variations / Q000235:genetics; D004249:DNA Damage / Q000502:physiology; D017931:DNA Primers / Q000235:genetics; D051747:DNA-Activated Protein Kinase / Q000378:metabolism; D005434:Flow Cytometry; D016679:Genome, Viral / Q000235:genetics*; D042822:Genomic Instability / Q000235:genetics*; D006801:Humans; D015603:Keratinocytes; D010957:Plasmids / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics / Q000502:physiology*
D017931:DNA Primers; D034741:RNA, Small Interfering; D016590:Aphidicolin; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D051747:DNA-Activated Protein Kinase; D017346:Protein Serine-Threonine Kinases